Cantor Fitzgerald Lowers Earnings Estimates for Immatics

Immatics (NASDAQ:IMTX) – Investment analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of Immatics in a research note issued to investors on Tuesday, April 1st. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings of ($1.53) per share for the year, down from their previous estimate of ($1.34). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share.

Immatics Stock Down 8.9 %

Immatics stock opened at $3.50 on Thursday. The company has a fifty day simple moving average of $4.81 and a 200-day simple moving average of $7.20. The firm has a market capitalization of $417.75 million, a price-to-earnings ratio of -5.30 and a beta of 0.85. Immatics has a 52-week low of $3.39 and a 52-week high of $13.77.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Thursday, March 27th. The company reported $0.48 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.51. The firm had revenue of $15.67 million during the quarter, compared to analysts’ expectations of $16.16 million. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%.

Institutional Trading of Immatics

Several large investors have recently bought and sold shares of the business. abrdn plc lifted its stake in Immatics by 49.2% in the 4th quarter. abrdn plc now owns 347,379 shares of the company’s stock worth $2,470,000 after purchasing an additional 114,479 shares in the last quarter. Wellington Management Group LLP lifted its position in Immatics by 1.5% during the third quarter. Wellington Management Group LLP now owns 9,681,183 shares of the company’s stock worth $110,462,000 after buying an additional 144,549 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its position in Immatics by 17.5% during the third quarter. Frazier Life Sciences Management L.P. now owns 1,354,711 shares of the company’s stock worth $15,457,000 after buying an additional 202,255 shares in the last quarter. State Street Corp grew its holdings in Immatics by 11.2% in the 3rd quarter. State Street Corp now owns 225,202 shares of the company’s stock valued at $2,570,000 after buying an additional 22,710 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Immatics by 9.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 164,766 shares of the company’s stock worth $1,880,000 after acquiring an additional 13,997 shares during the last quarter. Hedge funds and other institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.